Article Text

Download PDFPDF

Review: evidence from 2 low quality screening studies does not show a reduction in death from prostate cancer

Statistics from

 Q Does screening for prostate cancer reduce mortality?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★☆☆☆ Oncology ★★★★★★☆


Embedded ImageData sources:

PROSTATE register (up to November 2004), Cochrane Central Register of Controlled Trials, Medline, EMBASE/Excerpta Medica, CANCERLIT, NHS EED (all from 1966 to January 2006); hand searches of specialist journals: BJU International (2000–2005), European Urology (2002–2005), The Prostate (1998–2005), Journal of Urology (1996–2005), Urology (2002–2005), and Cancer (1998–2005); grey literature; and personal communication.

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) and quasi-randomised controlled trials (quasi-RCTs) in any language that compared screening with no screening for prostate cancer in men of any age. Screening procedures included digital rectal examination, prostate specific antigen test, or transrectal ultrasound biopsy. Studies evaluating the economic impact of screening for prostate cancer were also included. 1 RCT (n = 46 486) and 1 quasi-RCT (n = 9026) met the selection criteria. Quality assessment of individual …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.